{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:51:29Z","timestamp":1790088689444,"version":"4.0.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.rmed.2024.107722","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T23:38:47Z","timestamp":1719358727000},"page":"107722","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Direct oral anticoagulants in the treatment of chronic thromboembolic pulmonary hypertension patients: A retrospective cohort study"],"prefix":"10.1016","volume":"231","author":[{"given":"Ling-Tao","family":"Chong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Ting","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang-Shan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Qiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Rui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Xiao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5687-9830","authenticated-orcid":false,"given":"Lu","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2024.107722_bib1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/jth.14649","article-title":"A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension","volume":"18","author":"Bunclark","year":"2020","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.rmed.2024.107722_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02828-2020","article-title":"ERS statement on chronic thromboembolic pulmonary hypertension","volume":"57","author":"Delcroix","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2024.107722_bib3","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1016\/S0140-6736(16)30514-1","article-title":"Deep vein thrombosis and pulmonary embolism","volume":"388","author":"Di Nisio","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2024.107722_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019329","article-title":"The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1\/P-glycoprotein transporter","volume":"6","author":"Ding","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.rmed.2024.107722_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.rmed.2024.107722_bib6","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/S0735-1097(02)02139-3","article-title":"The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia","volume":"40","author":"Halcox","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.rmed.2024.107722_bib7","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet Lond Engl"},{"issue":"23","key":"10.1016\/j.rmed.2024.107722_bib8","first-page":"270","article-title":"Long-term outcome of chronic thromboembolic pulmonary hypertension using direct oral anticoagulants and warfarin: a Japanese prospective cohort study","volume":"S1538\u20137836","author":"Hosokawa","year":"2023","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.rmed.2024.107722_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.thromres.2019.05.018","article-title":"Use of direct oral anticoagulants prevents increase in pulmonary vascular resistance and incidence of clinical worsening in patients with chronic thromboembolic pulmonary hypertension","volume":"180","author":"Hosokawa","year":"2019","journal-title":"Thromb. Res."},{"key":"10.1016\/j.rmed.2024.107722_bib10","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s11239-021-02594-1","article-title":"The long-term survival in patients with chronic thromboembolic pulmonary hypertension: experience from a single center in China","volume":"53","author":"Hu","year":"2022","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.rmed.2024.107722_bib11","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.rmed.2024.107722_bib12","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.healun.2022.02.002","article-title":"Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension","volume":"41","author":"Humbert","year":"2022","journal-title":"J Heart Lung Transplant Off Publ Int Soc Heart Transplant"},{"key":"10.1016\/j.rmed.2024.107722_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/fcp.12504","article-title":"In vitro assessment of P-gp and BCRP transporter-mediated drug-drug interactions of riociguat with direct oral anticoagulants","volume":"34","author":"Jacqueroux","year":"2020","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.rmed.2024.107722_bib14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s40262-015-0322-y","article-title":"Physiologically-based pharmacokinetic modeling of macitentan: prediction of drug-drug interactions","volume":"55","author":"de Kanter","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.rmed.2024.107722_bib15","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01915-2018","article-title":"Chronic thromboembolic pulmonary hypertension","volume":"53","author":"Kim","year":"2019","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2024.107722_bib16","first-page":"548","article-title":"Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany","volume":"107","author":"Kramm","year":"2018","journal-title":"Clin Res Cardiol Off J Ger Card Soc"},{"key":"10.1016\/j.rmed.2024.107722_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.05.003","article-title":"Indications and potential pitfalls of anticoagulants in pulmonary hypertension: would DOACs become a better option than VKAs?","volume":"37","author":"Margelidon-Cozzolino","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.rmed.2024.107722_bib18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1124\/jpet.117.245993","article-title":"In vitro assessment of pharmacokinetic drug-drug interactions of direct oral anticoagulants: type 5-phosphodiesterase inhibitors are inhibitors of rivaroxaban and apixaban efflux by P-glycoprotein","volume":"365","author":"Margelidon-Cozzolino","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.rmed.2024.107722_bib19","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s11239-021-02445-z","article-title":"Direct oral anticoagulants in chronic thromboembolic pulmonary hypertension","volume":"52","author":"Porres-Aguilar","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.rmed.2024.107722_bib20","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.rmed.2024.107722_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/2045894019873545","article-title":"Real-life data of direct anticoagulant use, bleeding risk and venous thromboembolism recurrence in chronic thromboembolic pulmonary hypertension patients: an observational retrospective study","volume":"10","author":"Sena","year":"2020","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.rmed.2024.107722_bib22","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1002\/jps.21789","article-title":"No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers","volume":"98","author":"Spence","year":"2009","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.rmed.2024.107722_bib23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12561-021-09314-6","article-title":"Exposure adjusted incidence rate and event rate in clinical trials with treatment crossover","volume":"14","author":"Sui","year":"2022","journal-title":"Stat Biosci"},{"key":"10.1016\/j.rmed.2024.107722_bib24","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/cpt.2714","article-title":"Personalizing direct oral anticoagulant therapy for a diverse population: role of race, kidney function, drug interactions, and pharmacogenetics","volume":"113","author":"Thompson","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.rmed.2024.107722_bib25","doi-asserted-by":"crossref","first-page":"7769","DOI":"10.1038\/s41598-019-44190-7","article-title":"Sildenafil reduces neointimal hyperplasia after angioplasty and inhibits platelet aggregation via activation of cGMP-dependent protein kinase","volume":"9","author":"Yang","year":"2019","journal-title":"Sci. Rep."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611124001975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611124001975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T03:20:35Z","timestamp":1722655235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611124001975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":25,"alternative-id":["S0954611124001975"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2024.107722","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct oral anticoagulants in the treatment of chronic thromboembolic pulmonary hypertension patients: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2024.107722","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107722"}}